Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
Completed · Phase 1
Conditions studied: Healthy
In brief
The lack of clear guidelines and studies addressing the proper response to the pneumococcal vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our immunodeficiency patients. Should an age matched normal response range to the Pneumovax ® be established, it would have a profound impact in the diagnosis, safety and care of immunodeficiency patients. Moreover, characterizing the B cell compartments response to the Pneumovax ® may better delineate the mechanism of protective immunity from Pneumovax ® and provide an additional tool for the diagnosis and care for immunodeficiency patients.
Key facts
- Study ID
- NCT00589394
- Run by
- Mayo Clinic
- People needed
- 100
- Starts
- 2007-07-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2016-01-11
Who can join
Age: 20 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients from 20 to 70 years of age
You may not qualify if…
- Previous or current diagnosis of an immunodeficiency (primary and secondary)
- Previous or current diagnosis of a rheumatological disorders (Rheumatoid arthritis, Lupus, Sjögren, vasculitis), cancer, diabetes, active infection and/or other chronic diseases (multiple sclerosis, etc)
- Current or previous use (within that last 6 months) of systemic/inhaled corticosteroids, sulfasalazine, and other immunosuppressive agents (cyclosporin, methotrexate, CellCept) anti-convulsants (phenytoin, carbamazepine), gold, d-penicillamine, and anti-malarials (quinine, chloroquine, hydroxychloroquine)
- Pregnancy
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.